FY2025 · ended Dec 31, 2025 · Revenue $233.80M, +16.1% YoY · Filed Mar 2, 2026
Cerus Corp (CERS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $233.8 million and a net loss of $15.6 million. Free cash flow was $1.1 million. As of Sep 30, 2026 it held $57.1 million in cash and investments and $11.6 million in total debt.
Revenue
$233.80M
+16.1% vs prior year
Net income (TTM)
$-7.31M
+54.2% vs year-ago TTM
Operating cash flow (TTM)
$3.50M
-1.9% vs year-ago TTM
Free cash flow (TTM)
$494,000
+194.0% vs year-ago TTM
EPS (TTM)
$-0.04
+56.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
192.17M
+3.4% vs prior year
Net cash
$45.50M
as of Sep 30, 2026
Operating margin
-3.7%
FY 2025
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CERS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Concord, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1020214
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $233.8M | $201.3M | $186.8M | $188.3M | $159.5M |
| Operating income | -$8.7M | -$14.2M | -$30.1M | -$34.1M | -$48.9M |
| Net income | -$15.6M | -$20.9M | -$37.5M | -$42.8M | -$54.4M |
| Diluted EPS | -$0.08 | -$0.11 | -$0.21 | -$0.24 | — |
| Operating cash flow | $4.8M | $11.4M | -$43.2M | -$25.6M | -$33.9M |
| Free cash flow | $1.1M | $8.5M | -$47.8M | -$27.6M | -$34.8M |
| Total assets | $221.9M | $200.9M | $197.7M | $218.1M | $237.5M |
| Total liabilities | $156.9M | $144.0M | $144.3M | $149.5M | $151.9M |
| Stockholders' equity | $64.2M | $56.1M | $52.6M | $67.6M | $84.6M |
| Cash and investments | $82.9M | $80.5M | $65.9M | $102.2M | $129.4M |
| Total debt | $13.1M | $13.9M | $16.2M | $17.4M | $18.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jun 8, 2026 | Jun 5, 2026 |
All 1000 Cerus Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.